Bio-Rad Laboratories, Inc. Class A Common Stock vs Tesla, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Tesla, Inc. trades at $334.05 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 138.9× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| BIO | TSLA | |
|---|---|---|
Market Cap | $9.43B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $489.88 |
52-Week Low | $241.71 | $298.16 |
Enterprise Value | $9.18B | $1.29T |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tesla (TSLA) trades at $330.87, up 0.7% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key resistance at $333 and support at $327, while fundamentals reveal high valuation multiples (P/E 306.37) and declining profit margins (net margin 3.67% in 2025). Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, balancing near-term delivery misses with long-term innovation bets.
Tesla's outlook hinges on executing its pivot to AI and autonomy amid slowing auto growth. Investment opportunities lie in market leadership in self-driving technology and energy expansion, but risks include intense EV competition, execution challenges, and rich valuations that demand flawless growth. Wall Street remains divided, with a $393.87 consensus target suggesting upside if catalysts materialize.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →